Pranlukast
Grundinformationen
- CAS
103177-37-3- Standard-SMILES
O=C(Nc1cccc2c(=O)cc(-c3nn[nH]n3)oc12)c1ccc(OCCCCc2ccccc2)cc1- InChIKey
NBQKINXMPLXUET-UHFFFAOYSA-N- Summenformel
- C27H23N5O4
- Durchschnittliche Molmasse
- 481,5 g/mol
- Monoisotopische Masse
- 481,17500423
Überblick
N-[4-oxo-2-(2H-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide is a member of chromones.
Namen und Bezeichner
- Bevorzugter Name
- Pranlukast
- IUPAC
- N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
- Englischer Name
- Pranlukast
- Summenformel
- C27H23N5O4
- Molmasse
- 481.5
Namen und Synonyme
Pranlukast103177-37-3AzlaireOno-1078ONO 1078Ono-RS-411N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamideCCN 00401RS 411SB 205312pranlukastumONO-RS 411
Weitere Namen anzeigen
Ononrs411Ultairono1078PrenastPrandtlPranlukasemihydrate
DTXSID3043782CCN-00401RS-411SB-205312TB8Z891092DTXCID1023782N-(4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl)-p-(4-phenylbutoxy)benzamide8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4H-1-benzopyran
Datenbank-Bezeichner
- CAS
103177-37-3- PubChem CID
- 4887
- DTXSID
DTXSID3043782- ChEMBL
CHEMBL11350、CHEMBL21333- ChEBI
CHEBI:94810- UNII
- TB8Z891092
- EC Number
- 808-178-9
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 4,2
- Polarare Oberfläche (TPSA)
- 119 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 7
- Frei drehbare Bindungen
- 9
- Schwere Atome
- 36
- Formalladung
- 0
- Komplexität
- 778
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Listed in ZINC15
Physikochemische Eigenschaften
- Schmelzpunkt
- 236 · 236-238°C
- Dichte
- 1.374 · 1.374±0.06 g/cm3(Predicted)
- storage temp.
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- Löslichkeit
- Soluble in DMSO (up to 25 mg/ml)
- pka
- 4.96 · 4.96±0.10(Predicted)
- Aggregatzustand
- solid
- Farbe
- White
- Merck
- 14 · 14,7710
- Stabilität
- 1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
- InChIKey
- NBQKINXMPLXUET-UHFFFAOYSA-N
- SMILES
- C(NC1=C2OC(C3=NNN=N3)=CC(=O)C2=CC=C1)(=O)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
- CAS Datenbank
- 103177 · 103177-37-3(CAS DataBase Reference)
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Gefahrenhinweise
Hazard Classes and CategoriesSkin Irrit. 2 (100%)
Toxikologische Informationen
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Pranlukast
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
Sicherheitsdaten
- hs_code
- 2934.99.4400
- RTECS-Nr.
- CV5647500
- risk_code
- 11-34
- Toxizität
- LD50 in male mice (mg/kg): >1000 i.v. (Toda)
- hazard_code
- F,C
- safety_code
- 16-26-36/37/39-45
Chemie und Industrie
Pharmakologische Informationen
ATC Code
R - Respiratory system
QR - Respiratory system
PharmacodynamicsPranlukast is a cysteinyl leukotriene receptor-1 antagonist.
Mechanism of Action
Pranlukast selectively antagonizes leukotriene D<sub>4</sub> (LTD<sub>4</sub>) at the cysteinyl leukotriene receptor, CysLT<sub>1</sub>, in the human airway. Pranlukast inhibits the actions of LTD<sub>4</sub> at the CysLT<sub>1</sub> receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Metabolism/MetabolitesHepatic
MeSH Pharmacological Classification
Drugs that are used to treat asthma.
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
Anwendungen
BeschreibungPranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD4 receptor. In patients with bronchial asthma, pranlukast was reported to induce significant improvement in both immediate and late asthmatic response induced by antigen. Pranlukast is also being evaluated clinically for the treatment of perennial allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested.
VerwendenLabeled Pranlukast, intended for use as an internal standard for the quantification of Pranlukast by GC- or LC-mass spectrometry.
Vor- und nachgelagerte Produkte
Zugehörige Reaktionen
1
Notizen zur Verbindung
Wird geladen…